StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Down 5.9 %

Shares of PULM opened at $1.89 on Monday. The firm has a market cap of $6.90 million, a P/E ratio of -0.49 and a beta of 0.92. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $3.14. The company’s 50-day moving average price is $1.80 and its 200 day moving average price is $1.88.

Institutional Trading of Pulmatrix

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Pulmatrix by 7.3% during the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Pulmatrix during the second quarter worth approximately $141,000. Mariner LLC purchased a new stake in shares of Pulmatrix during the fourth quarter worth approximately $97,000. Susquehanna International Group LLP acquired a new position in Pulmatrix in the first quarter valued at approximately $73,000. Finally, Vanguard Group Inc. boosted its holdings in Pulmatrix by 62.9% in the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 13,548 shares in the last quarter. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.